Please Wait.....
Report
Diffuse Large B-cell Lymphoma (DLBCL) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Market Report (15 days) I 2024-04-23 I 216 Pages I IMARC Group
The 7 major Diffuse Large B-cell Lymphoma (DLBCL) markets reached a value of US$ 3,907.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,257.7 Million by 2034, exhibiting a growth rate (CAGR) of 2.7% during 2024-2034.
Diffuse Large B-cell Lymphoma (DLBCL) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the geriatric population and rising safety and efficacy of current and emerging therapies, etc. Diffuse Large B-Cell Lymphoma, a form of non-Hodgkin lymphoma, represents the most common blood cancer. Lymphomas develop when immune cells, known as B lymphocytes, grow and multiply in an uncontrolled way. DLBCL develops mostly in adults and is a rapidly-growing (aggressive) lymphoma. It can begin in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Usually, the first symptoms of DLBCL is a painless swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. This swelling can also be painful for some people. Other symptoms of DLBCL may include night sweats, unexplained fevers, and a loss in weight. DLBCL can occur at any age, however, it is generally rare in children and is more common in older people. Most people diagnosed with DLBCL are usually 60 or over. Furthermore, DLBCL affects slightly more males than females. Other risk factors include family history, certain infections, weakened immune system, obesity, exposure to certain chemicals, etc.
IMARC Group's new report "Diffuse Large B-cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Diffuse Large B-cell Lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Diffuse Large B-cell Lymphoma market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Diffuse Large B-cell Lymphoma across the seven major markets. According to the report the United States has the largest patient pool for Diffuse Large B-cell Lymphoma and also represents the largest market for Diffuse Large B-cell Lymphoma treatment. Furthermore, the current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Diffuse Large B-cell Lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Diffuse Large B-cell Lymphoma Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Diffuse Large B-cell Lymphoma Market
Sales of Various Drugs Across the Diffuse Large B-cell Lymphoma Market
Reimbursement Scenario in the Diffuse Large B-cell Lymphoma Market
Competitive Landscape:
This report also provides a detailed analysis of the current Diffuse Large B-cell Lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Diffuse Large B-cell Lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Diffuse Large B-cell Lymphoma market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Diffuse Large B-cell Lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Diffuse Large B-cell Lymphoma market?
Epidemiology Insights
What is the size of the Diffuse Large B-cell Lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Diffuse Large B-cell Lymphoma across the seven major markets?
What are the key factors driving the epidemiological trend of Diffuse Large B-cell Lymphoma?
What will be the growth rate of Diffuse Large B-cell Lymphoma patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Diffuse Large B-cell Lymphoma drugs and what are their market performance?
What are the key pipeline Diffuse Large B-cell Lymphoma drugs and how are they expected to perform in the coming years?
How safe are the current marketed Diffuse Large B-cell Lymphoma drugs and what are their efficacies?
How safe are the late-stage pipeline Diffuse Large B-cell Lymphoma drugs and what are their efficacies?
What are the current treatment guidelines for Diffuse Large B-cell Lymphoma drugs across the seven major markets?
Who are the key companies in the Diffuse Large B-cell Lymphoma market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Diffuse Large B-cell Lymphoma market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Diffuse Large B-cell Lymphoma - Introduction
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 Diffuse Large B-cell Lymphoma - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Diffuse Large B-cell Lymphoma - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 Diffuse Large B-cell Lymphoma - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Diffuse Large B-cell Lymphoma Guidelines, Management and Treatment
8.2 Diffuse Large B-cell Lymphoma Treatment Algorithm
9 Diffuse Large B-cell Lymphoma - Unmet Needs
10 Diffuse Large B-cell Lymphoma - Key Endpoints of Treatment
11 Diffuse Large B-cell Lymphoma - Marketed Products
11.1 List of Diffuse Large B-cell Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Diffuse Large B-cell Lymphoma - Pipeline Products
12.1 List of Diffuse Large B-cell Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Sales Outlook
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 Diffuse Large B-cell Lymphoma - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Diffuse Large B-cell Lymphoma - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Diffuse Large B-cell Lymphoma - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034)?
14.3 Market Scenario - United States
14.3.1 Diffuse Large B-cell Lymphoma - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Diffuse Large B-cell Lymphoma - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Diffuse Large B-cell Lymphoma - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Diffuse Large B-cell Lymphoma - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Diffuse Large B-cell Lymphoma - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Diffuse Large B-cell Lymphoma - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Diffuse Large B-cell Lymphoma - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
15 Diffuse Large B-cell Lymphoma - Recent Events and Inputs From Key Opinion Leaders
16 Diffuse Large B-cell Lymphoma Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 Appendix
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security